Department of Neurology, The First Hospital of Jilin University, Changchun 130012, China.
Department of Intensive Care Medicine, The First Hospital of Jilin University, Changchun 130012, China.
Biomed Pharmacother. 2023 Oct;166:115361. doi: 10.1016/j.biopha.2023.115361. Epub 2023 Sep 4.
Gastrointestinal tumors remain a significant healthcare burden worldwide, necessitating the development of innovative therapeutic strategies. mRNA vaccines have emerged as a promising approach in cancer immunotherapy, harnessing the immune system's potential to recognize and eliminate tumor cells. mRNA vaccines offer several advantages, including their ability to elicit both innate and adaptive immune responses, ease of production, and adaptability to different tumor types. In the context of gastrointestinal tumors, mRNA vaccines hold great potential as a therapeutic strategy. In this review, we will delve into the immunomodulatory mechanisms and immunotherapy strategies of mRNA vaccines in gastrointestinal tumors. Additionally, we will discuss the challenges and ongoing research efforts in optimizing mRNA vaccine development, delivery, and stability. By understanding the potential of mRNA vaccines in addressing the unmet medical need of gastrointestinal tumors, we aim to pave the way for improved treatment strategies and better patient outcomes.
胃肠道肿瘤仍然是全球范围内的重大医疗负担，需要开发创新的治疗策略。mRNA 疫苗在癌症免疫治疗中崭露头角，利用免疫系统识别和消除肿瘤细胞的潜力。mRNA 疫苗具有许多优势，包括能够引发先天和适应性免疫反应、易于生产以及适应不同肿瘤类型的能力。在胃肠道肿瘤的背景下，mRNA 疫苗作为一种治疗策略具有巨大的潜力。在这篇综述中，我们将深入探讨 mRNA 疫苗在胃肠道肿瘤中的免疫调节机制和免疫治疗策略。此外，我们将讨论优化 mRNA 疫苗开发、传递和稳定性方面的挑战和正在进行的研究工作。通过了解 mRNA 疫苗在满足胃肠道肿瘤未满足的医疗需求方面的潜力，我们旨在为改善治疗策略和提高患者预后铺平道路。
